Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Laws

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Drugs in Dermatology : JDD|April 14, 2021
Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase)Richard B Warren, Michael Gold, Melinda Gooderham, et al.
JAMA Dermatology|March 5, 2025
Effectiveness of Adalimumab Biosimilars and Originator for PsoriasisDuc Binh Phan, Anthony P Bewley, Philip Laws, et al.
Clinical and Experimental Dermatology|May 22, 2025
Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohortOras A Alabas, Ian Evans, Kathleen Mcelhone, et al.
The British Journal of Dermatology|March 16, 2026
Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Duc Binh Phan, Philip Laws, Catherine H Smith, et al.
BMJ Open|February 15, 2023
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)Matthias Augustin, Rachel Sommer, Esteban Daudén, et al.
The British Journal of Dermatology|September 5, 2024
An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024Michael R Ardern-Jones, Sara J Brown, Carsten Flohr, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Drugs in Dermatology : JDD|April 14, 2021
Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase)Richard B Warren, Michael Gold, Melinda Gooderham, et al.
JAMA Dermatology|March 5, 2025
Effectiveness of Adalimumab Biosimilars and Originator for PsoriasisDuc Binh Phan, Anthony P Bewley, Philip Laws, et al.
Clinical and Experimental Dermatology|May 22, 2025
Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohortOras A Alabas, Ian Evans, Kathleen Mcelhone, et al.
The British Journal of Dermatology|March 16, 2026
Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Duc Binh Phan, Philip Laws, Catherine H Smith, et al.
BMJ Open|February 15, 2023
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study)Matthias Augustin, Rachel Sommer, Esteban Daudén, et al.
The British Journal of Dermatology|September 5, 2024
An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024Michael R Ardern-Jones, Sara J Brown, Carsten Flohr, et al.
Pageof 2